Bill
SB 444
Expands NC drug law to schedule many new synthetic opioids, fentanyl analogs, nitazenes, synthetic cannabinoids, cathinones, tryptamines, and bromazolam, broadening criminal penalt
Summary
- Purpose: to update North Carolina’s Controlled Substances Act (G.S. 90‑89) by adding multiple newly identified synthetic opioids, fentanyl analogs, nitazene compounds, synthetic cannabinoids, substituted cathinones, certain tryptamines and benzodiazepine analogs to existing schedules. The changes broaden the statutory definitions used to criminalize manufacture, distribution, possession, and other regulated activities for those substances (including salts, isomers, esters, ethers, homologues where specified).
Key substantive provisions
- Expands the list of opiates/opioids to include numerous U‑series compounds and analogs (e.g., many U‑47700 variants and related derivatives listed explicitly).
- Broadens the scope for fentanyl derivatives by defining any compound structurally derived from fentanyl by substitution/replacement on key groups (phenethyl, piperidine ring, propanamide, anilido phenyl), and lists specific examples (e.g., 2‑, 3‑, and 4‑fluorofentanyl/related isobutyryl and butyryl analogs).
- Adds a new subdivision for Nitazene derivatives (the N‑substituted benzimidazole class), defined expansively by structural features and by multiple possible substitutions; includes salts and isomers. The provision includes narrow exceptions for industrial manufacturing processes not intended for human ingestion, FDA‑approved prescription use under medical supervision, and recognized research use.
- Updates Schedule entries for hallucinogens/tryptamines (corrects/clarifies 5‑MeO‑MiPT nomenclature).
- Adds Bromazolam to benzodiazepine listings.
- Rewrites/clarifies language for substituted cathinones (excluding bupropion), including specific structural change tests and an inclusive definition of “isomer.”
- Expands the “synthetic cannabinoids” description and adds specific structural subtypes (e.g., indole carboxamides), with examples and language covering salts, isomers, homologues.
- Technical drafting: many cross‑references, inclusion of salts/isomers/esters/ethers/homologues where chemically possible, and carve‑outs for FDA‑approved products and legitimate research/industrial uses.
Who is affected
- Law enforcement and prosecutors: broader statutory authority to charge and prosecute possession, manufacture, distribution, and trafficking involving the newly listed substances and their analogs.
- Health care providers, researchers, and industry: researchers and manufacturers handling listed chemicals must confirm whether a statutory exception applies; those conducting legitimate research or manufacturing must be aware of exceptions and recordkeeping/permit requirements.
- Public health and treatment systems: potential increase in enforcement actions and possible changes in overdose response patterns as previously novel synthetic drugs are scheduled.
- General public: changes mean broader coverage by criminal statutes for many emerging synthetic drugs.
Procedural and timeline notes
- Sponsor (primary for NC): Senator Harry L. “Harry” (Hanig) (listed as primary sponsor in provided materials).
- Legislative action highlights (selected):
- Introduced in 2025; multiple committee referrals and amendments in March–April 2025.
- Passed both chambers in spring 2025 (Senate and House actions documented in March–April 2025).
- Enrolled, delivered to the Governor and reported as enacted: notification in records indicates the bill became Act 970 in April 2025.
- Effective date: the enacted law (Act 970) took effect according to the normal rules for bills in that session (see State enactment notices for the precise effective date).
Potential impacts and considerations
- Public safety: expands prosecutors’ tools against new synthetic opioids and designer drugs implicated in overdose deaths.
- Research and medical uses: the statute includes limited exceptions for FDA‑approved products and bona fide research; however, the broad structural definitions mean practitioners and labs should verify compliance and potential licensing/registration needs.
- Enforcement/forensics: broader schedules will require updated forensic testing protocols and training for identification of newly listed compounds.
Note: This summary focuses on the North Carolina SB 444 materials included among the provided documents. Other jurisdictions use the same bill number for unrelated measures; those are not covered here.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
